ABSTRACT
Targeted drug combined with chemotherapy have become the trend in treatment of advanced colorectal cancer, one of the most common cancers worldwide. To date, nearly ten targeted drugs have been approved for clinical use, helping to extend patients' lifetime by months or even years. Meanwhile, with the exploration in etiology and molecular pathogenesis, new targeted drugs come forth continuously. However, problems remain in various aspects, such as ways to dealing with drug resistance, individualized drug choice and treatment decisions. This review article described the achievements and challenges in targeted therapy for colorectal cancer.
ABSTRACT
Apolipoprotein A-I (apoA-I) is a member of the apolipoprotein A family, which was discovered the earli-est. It has an important role in the regulation of lipid metabolism, which mainly includes cholesterol synthesis and transfer. Therefore, apoA-I is closely related to hyperlipidemia and atherosclerosis. Clinically, serum ApoA-I/ApoB has been used as one of the indexes of hyperlipidemia. This article reviewed the study progress in ApoA-I's gene polymorphism and its relationship with reverse cholesterol transport (RCT).